An active metabolite of tryptophan and an NMDA receptor agonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Quinolinic Acid

Item No. 14941

Technical Information
Formal Name
2,3-pyridinedicarboxylic acid
CAS Number
89-00-9
Synonyms
  • NSC 13127
  • NSC 18836
  • NSC 403247
Molecular Formula
C7H5NO4
Formula Weight
Purity
≥98%
A crystalline solid
DMF: 16 mg/mlDMSO: 16 mg/mlPBS (pH 7.2): 0.5 mg/ml
λmax
216, 264 nm
SMILES
O=C(O)C1=CC=CN=C1C(O)=O
InChi Code
InChI=1S/C7H5NO4/c9-6(10)4-2-1-3-8-5(4)7(11)12/h1-3H,(H,9,10)(H,11,12)
InChi Key
GJAWHXHKYYXBSV-UHFFFAOYSA-N
Origin
Synthetic
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Product Description

    Quinolinic acid is an active metabolite of tryptophan (Item Nos. 29600 | 31210) and an NMDA receptor agonist.1,2 It is formed from tryptophan via the kynurenine pathway.1 Quinolinic acid (100 µM) induces lipid peroxidation in rat brain synaptosomes, an effect that can be reversed by the NMDA receptor antagonist 2-amino-5-phosphonovaleric acid.3 It decreases the viability of primary rat neurons when used at a concentration of 25 µM.4 Intracerebroventricular administration of quinolinic acid (1 µg/animal) induces convulsions in mice.5 Increased plasma levels of quinolinic acid negatively correlate with Brief Neurocognitive Assessment (BNA) scores in patients with schizophrenia.6

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Heyes, M.P., Achim, C.L., Wiley, C.A., et alHuman microglia convert L-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 320(2), 595-597 (1996).

    2. Stone, T.W., and Perkins, M.N. Quinolinic acid: A potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 72(4), 411-412 (1981).

    3. Carpenedo, R., Meli, E., Peruginelli, F., et alKynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures. J. Neurochem. 82(6), 1465-1471 (2002).

    4. Lisak, R.P., Nedelkoska, L., Bealmear, B., et alMelanocortin receptor agonist ACTH 1-39 protects rat forebrain neurons from apoptotic, excitotoxic and inflammation-related damage. Exp. Neurol. 273, 161-167 (2015).

    5. Lapin, I.P. Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice. J. Neural. Transm. 42(1), 37-43 (1978).

    6. Cathomas, F., Guetter, K., Seifritz, E., et alQuinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. Sci. Rep. 11(1), 9992 (2021).